Communiqués Zai Lab Limited Hong Kong S.E.

Actions

9688

KYG9887T1168

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:12 14/06/2024			Varia. 5j.	Varia. 1 janv.
14,84 ^HKD	-6,43%		-1,46%	-30,98%

14/06	Les actions asiatiques négociées aux Etats-Unis et les American Depositary Receipts tendent à la baisse dans les échanges de vendredi	MT
12/06	Transcript : Zai Lab Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D	11/06	BU
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22/05	BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	21/05	AQ
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20/05	BU
Zai Lab Announces Participation in May and June Investor Conferences	16/05	BU
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China	14/05	BU
Zai Lab Announces Approval of AUGTYRO for Patients with ROS1-positive NSCLC by China's NMPA	13/05	AQ
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA	13/05	BU
Zai Lab : Corporate Presentation	09/05	PU
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates	08/05	BU
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024	15/04	BU
Zai Lab Statement on Executive Management Team's Agreement on Share Activities	12/04	AQ
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities	11/04	BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint	02/04	AQ
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs	02/04	BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...	01/04	BU
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	28/03	AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	27/03	BU
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors	14/03	BU
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)	06/03	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Zai Lab Limited Hong Kong S.E.

Actions

9688

KYG9887T1168

Communiqués

Filtres